Jacobi Capital Management’s Idexx Laboratories IDXX Stock Holding History

Jacobi Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-394	Closed	-$221K	–	658
2026 Q1	$221K	Buy	+394	New	+$253K	0.01%	599
2021 Q4	–	Sell	-260	Closed	-$162K	–	821
2021 Q3	$162K	Buy	+260	New	+$175K	0.02%	436
2021 Q1	–	Sell	-2	Closed	-$1K	–	1401
2020 Q4	$1K	Buy	+2	New	+$895	﹤0.01%	1236

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Jacobi Capital Management's IDXX Position: Q2 2026 in Review

Jacobi Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 394 shares — an estimated $221K sold.

Jacobi Capital Management first reported a position in IDXX in Q4 2020 and held it in 3 quarters. The position peaked at $221K in Q1 2026. 1,303 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Jacobi Capital Management reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
Jacobi Capital Management sold 394 Idexx Laboratories shares in Q2 2026, an estimated $221K.
Jacobi Capital Management first reported a position in Idexx Laboratories in Q4 2020 and held it in 3 quarters.
Jacobi Capital Management's Idexx Laboratories position peaked at $221K in Q1 2026.
1,303 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Jacobi Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.